• 'Cobalt Labs Settles With GlaxoSmithKline (KiplingerForecasts.com)
  (AP) BONITA SPRINGS, Fla. Cobalt Laboratories Inc., a U.S. unit of Arrow Pharmaceuticals Inc., said Wednesday it reached a settlement with GlaxoSmithKline PLC over a patent dispute for a tablet version of migraine treatment Imitrex.



• 'Cobalt Labs Settles With GlaxoSmithKline (AP via Yahoo! Finance)
  Cobalt Laboratories Inc., a U.S. unit of Arrow Pharmaceuticals Inc., said Wednesday it reached a settlement with GlaxoSmithKline PLC over a patent dispute for a tablet version of migraine treatment Imitrex.



• 'Spectrum, GSK settle Imitrex patent litigation (PharmaBiz)
  Spectrum Pharmaceuticals, Inc. has settled a patent litigation with GlaxoSmithKline relating to sumatriptan injection, the generic version of GlaxoSmithKline's Imitrex Injection.



• 'Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation (FinanzNachrichten)
  IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, ( Nachrichten ) Inc. today announced that it has settled a patent litigation with GlaxoSmithKline ( Nachrichten / Aktienkurs ) relating to sumatriptan injection, the generic version of GlaxoSmithKline's Imitrex Injection.



• 'Cobalt Labs settles with GlaxoSmithKline (Sharewatch)
  The settlement, which still must pass Federal Trade Commission review, allows Cobalt to begin selling tablets of sumatriptan succinate, the active ingredient in Imitrex, in the first quarter of 2009. GlaxoSmithKline confirmed the settlement agreement was undergoing federal review, and said that a trial had been set to begin in October.



• 'GSK Brands Shift to IPG (AdWeek)
  NEW YORK Three Interpublic Group shops have landed ad duties on GlaxoSmithKline brands in five categories that previously were split between WPP Group agencies Grey Healthcare and Thomas Ferguson Associates, sources said.



• 'Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation (FinanzNachrichten)
  WOODCLIFF LAKE, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Par Pharmaceutical ( Nachrichten ) Companies, Inc. today announced that its partner, Spectrum Pharmaceuticals, Inc., has entered into a settlement agreement with GlaxoSmithKline ( Nachrichten / Aktienkurs ) (GSK) that resolves U.S. patent litigation related to GSK's Imitrex(R) Injection, thereby eliminating the inherent uncertainty and costs



• 'Cobalt Announces Settlement of Imitrex(R) Litigation With GlaxoSmithKline (PR Newswire via Yahoo! Finance)
  Cobalt Laboratories Inc. , on behalf of its affiliate Cobalt Pharmaceuticals Inc., announced today that is has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's Imitrex® tablets.



• 'Cobalt settles Imitrex litigation with Glaxo (Pharmaceutical Business Review)
  Cobalt Laboratories has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GSKs Imitrex tablets.



• 'Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation (PR Newswire via Yahoo! Finance)
  Par Pharmaceutical Companies, Inc. today announced that its partner, Spectrum Pharmaceuticals, Inc., has entered into a settlement agreement with GlaxoSmithKline that resolves U.S. patent litigation related to GSK's Imitrex® Injection, thereby eliminating the inherent uncertainty and costs of litigation.

Back to Imitrex News Archive

Imitrex